Global Point-of-Care Glucose Testing Market Size Likely to Reach at a CAGR of 4.5% By 2033

As per the current market research conducted by the CMI Team, the global Point-of-Care Glucose Testing Market size is expected to record a CAGR of 4.5% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 3,670.9 Million. By 2033, the valuation is anticipated to reach USD 5,455.3 Million.

Point-of-Care Glucose Testing Market: Growth Factors and Dynamics

• Rising Prevalence of Diabetes: The increasing incidence of diabetes worldwide is a major driver for the point-of-care glucose testing market. As diabetes management requires regular monitoring of blood glucose levels, there is a growing demand for convenient and accessible testing solutions, driving market growth.

• Technological Advancements: Ongoing advancements in point-of-care glucose testing technologies, such as continuous glucose monitoring (CGM) systems and miniaturized glucometers, enhance accuracy, ease of use, and data accessibility. These innovations attract both healthcare professionals and patients, fostering market expansion.

• Growing Adoption of Self-Monitoring: The shift towards patient-centered care and self-management of chronic conditions, including diabetes, is driving the demand for point-of-care glucose testing devices. Patients increasingly prefer self-monitoring solutions that offer real-time data and empower them to make informed decisions about their health.

• Increasing Awareness and Screening Programs: Public health initiatives aimed at diabetes prevention, early detection, and management contribute to market growth. Awareness campaigns, screening programs, and healthcare policies promoting regular blood glucose monitoring drive the adoption of point-of-care testing devices in various healthcare settings.

• Expanding Geriatric Population: The aging population, particularly in developed regions, drives market growth as older adults are at a higher risk of developing diabetes and require frequent monitoring of blood glucose levels. The increasing geriatric population creates a sustained demand for point-of-care glucose testing devices and services.

• Shift towards Homecare Settings: The preference for home-based healthcare solutions and the COVID-19 pandemic’s impact on healthcare delivery has accelerated the adoption of point-of-care glucose testing in homecare settings. Patients value the convenience, privacy, and safety of self-monitoring devices, driving market expansion beyond traditional clinical settings.

• Integration of Digital Health Solutions: Increasing integration of point-of-care glucose testing devices with digital health platforms and mobile applications enhances data management, analysis, and remote monitoring capabilities. This integration allows healthcare providers to track patients’ glucose levels in real time, offer personalized recommendations, and intervene promptly, driving market growth and improving patient outcomes.

• Focus on Preventive Healthcare: Growing emphasis on preventive healthcare, driven by rising healthcare costs and the burden of chronic diseases, fuels the demand for point-of-care glucose testing. Early detection of abnormal glucose levels enables timely interventions, lifestyle modifications, and disease management strategies, contributing to improved population health outcomes and driving market expansion.

Point-of-Care Glucose Testing Market: Partnership and Acquisitions

• In 2024, DexCom introduced its real-time continuous glucose monitoring (CGM) system, Dexcom ONE+, in Spain, Belgium, and Poland. The device was also launched on February 12. Dexcom plans to expand its availability to the Middle East, Africa, and additional European countries shortly.

• In 2023, Avricore Health and Ascensia Diabetes Care announced a partnership to integrate blood glucose monitoring (BGM) into point-of-care testing. The collaboration aims to incorporate Contour Next-Gen and Contour Next One BGM systems into Avricore’s HealthTab PCOT platform for enhanced healthcare solutions.

• In 2021, EKF Diagnostics launched the STAT-Site WB handheld analyzer globally, providing rapid -ketone and glucose measurements from whole blood within seconds. This reagent-free analyzer delivers quantitative results for -ketones and glucose in just 10 seconds and 5 seconds, respectively, enhancing efficiency in blood glucose management.

Report Scope

Point-of-Care Glucose Testing Market: COVID-19 Analysis

The COVID-19 pandemic has significantly impacted the Point-of-Care Glucose Testing Market, with the industry experiencing both positive and negative effects. Here are some of the key impacts:

• Disruption in Healthcare Services: During the COVID-19 pandemic, healthcare systems faced significant disruptions, with resources diverted to manage the outbreak. Non-urgent medical appointments and routine screenings, including glucose testing, were postponed or canceled, leading to a temporary decline in demand for point-of-care glucose testing devices and services.

• Shift in Patient Behavior: Fear of contracting the virus and lockdown measures led to changes in patient behavior, including reluctance to visit healthcare facilities for routine check-ups and tests. This resulted in reduced utilization of point-of-care glucose testing devices, particularly in clinical settings, impacting market demand.

• Telehealth and Remote Monitoring: Increased adoption of telehealth and remote monitoring solutions facilitated the continuity of glucose monitoring during the pandemic. Healthcare providers and patients embraced virtual consultations and remote monitoring platforms, ensuring ongoing management of diabetes and driving demand for point-of-care glucose testing devices.

• Homecare Solutions: The pandemic accelerated the shift towards home-based healthcare solutions, including point-of-care glucose testing devices. Patients increasingly relied on self-monitoring devices to manage their diabetes from the comfort and safety of their homes, driving market demand and innovation in homecare glucose testing solutions.

• Resumption of Routine Healthcare Services: As healthcare systems adapted to the challenges posed by the pandemic, routine healthcare services, including glucose testing, gradually resumed. Healthcare facilities implemented safety protocols to mitigate the risk of virus transmission, restoring patient confidence and utilization of point-of-care glucose testing devices.

• Focus on Chronic Disease Management: The COVID-19 pandemic underscored the importance of chronic disease management, including diabetes, in safeguarding public health. Healthcare providers and policymakers prioritized initiatives to address chronic disease burden, driving investment in point-of-care glucose testing solutions and promoting their integration into comprehensive disease management programs.

In conclusion, the COVID-19 pandemic has had a mixed impact on the Point-of-Care Glucose Testing Market, with some challenges and opportunities arising from the pandemic.

List of the prominent players in the Point-of-Care Glucose Testing Market:

• Abbott Laboratories
• Hoffmann-La Roche Ltd.
• Ascensia Diabetes Care Holdings AG
• Dexcom Inc.
• Medtronic plc
• LifeScan Inc. (A Johnson & Johnson Company)
• Becton Dickinson and Company
• Acon Laboratories Inc.
• Nova Biomedical Corporation
• ARKRAY Inc.
• Trividia Health Inc.
• PTS Diagnostics
• Nipro Diagnostics Inc.
• Ypsomed Holding AG
• Sanofi S.A.
• Others

The Point-of-Care Glucose Testing Market is segmented as follows:

By Product

• Accu Check Aviva Meter
• Onetouch Verio Flex
• i-STAT
• Bayer CONTOUR Blood Glucose Monitoring System
• Freestyle Lite
• True Metrix
• Accu-Chek Inform II
• StatStrip
• Others

By Technology

• Glucose Oxidase Based Testing
• Glucose Dehydrogenase Based Testing
• Others

By Application

• Type-1 Diabetes
• Type-2 Diabetes

By End Users

• Hospitals and Clinics
• Home Care Settings
• Others

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America